The Oncologist: The efficacy of lenvatinib with or without everolimus (Len ± Eve) in the treatment of metastatic renal cell carcinoma (mRCC)

Lenvatinib (Len) combined with everolimus (Eve) is approved for the treatment of metastatic renal cell carcinoma (mRCC) after the development of first-line vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs)
.
However, after the advancement of the combination therapy of immune checkpoint inhibitors (ICIs) and VEGFR-TKIs, there are limited data on the efficacy of Len±Eve

.

Lenvatinib (Len) combined with everolimus (Eve) is approved for the treatment of metastatic renal cell carcinoma (mRCC) after the development of first-line vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs)

Forty-two patients (76.

4%) received lenvatinib combined with everolimus, and 13 patients (23.

Forty-two patients (76.

At the time of analysis, 48 ​​patients experienced disease progression or death, and the median progression-free survival (PFS) of all patients was 6.

Overall population PFS and OS

Overall population PFS and OS

The confirmed ORR of the overall population was 21.

8%, and one patient achieved complete remission (CR)

The confirmed ORR of the overall population was 21.

Efficacy evaluation

Efficacy evaluation

Of the 13 patients who received lenvatinib alone, 9 had previously used everolimus and 1 had previously used temsirolimus, so they no longer used everolimus

.

Of the 13 patients who received lenvatinib alone, 9 had previously used everolimus and 1 had previously used temsirolimus, so they no longer used everolimus

Adverse events

Adverse events

In summary, studies have shown that after the advancement of the combination therapy of immune checkpoint inhibitors (ICIs) and VEGFR-TKIs, lenvatinib combined with or without everolimus (Len ± Eve) in the treatment of metastatic renal cell carcinoma (mRCC) has Certain curative effect and controllable toxicity

.

In summary, studies have shown that after the advancement of the combination therapy of immune checkpoint inhibitors (ICIs) and VEGFR-TKIs, lenvatinib combined with or without everolimus (Len ± Eve) in the treatment of metastatic renal cell carcinoma (mRCC) has Certain curative effect and controllable toxicity

Original source:

Wiele AJ, Bathala TK, Hahn AW, Xiao L, Duran M, Ross JA, Jonasch E, Shah AY, Campbell MT, Msaouel P, Tannir NM.
Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
Oncologist.
2021 Jun;26(6):476-482.
doi: 10.
1002/onco.
13770.
Epub 2021 Apr 21.
PMID: 33792094; PMCID: PMC8176993.

Wiele AJ, Bathala TK, Hahn AW, Xiao L, Duran M, Ross JA, Jonasch E, Shah AY, Campbell MT, Msaouel P, Tannir NM.
Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
Oncologist.
2021 Jun;26(6):476-482.
doi: 10.
1002/onco.
13770.
Epub 2021 Apr 21.
PMID: 33792094; PMCID: PMC8176993.
Leave a message here